Columbus, Ohio-based Visiox Pharmaceuticals announced on August 20 that it entered into a definitive merger agreement with Ocuvex Therapeutics, Inc.
Ocuvex Therapeutics is a privately held ophthalmic pharmaceutical company focused on developing and commercializing novel therapies for glaucoma and other disorders. It boasts a pipeline of near-term ophthalmic medicines.
Visiox Pharmaceuticals is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options.
Visiox’ products, including OMLONTI® (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35% and SDN-037 (difluprednate) 0.04%, will grow Ocuvex’s market presence and accelerate the commercialization of these therapeutics.
The strategic combination is set to position the newly combined entity as an emerging player in the eye care sector with a portfolio of ophthalmic medicines. Going forward, the company will operate under the Ocuvex name, building on Visiox’s commitment to improve the ophthalmic market through collaborations with eye care professionals. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 39th Pharmaceutical transaction of the year. There were 107 Pharmaceutical deals announced during 2023, and 96 announced during 2022.
